ProteinAGforADA-KCASBio Blogs
Read article Protein A/G Bead Capture for an ADA Assay: Using the Drug’s Structure to Our Advantage 

The challenge  The sponsor asked us to develop and validate an electrochemiluminescence (ECL) ligand binding assay (LBA) to detect anti-drug antibodies (ADA) in human serum to support clinical studies. The therapeutic is a bispecific conjugated fusion protein with two functional domains, FD1 and FD2. Furthermore, FD1 has…

ADC Antibody Drug Conjugate Molecule Linker Payload Protein Posters & Papers
Read article Quantification of antibody–drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies

This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…

Enzyme-linked immunosorbent assay (ELISA), Immunology testing method in laboratory Posters & Papers
Read article Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies

This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…

Antibody drug conjugate delivering cytotoxic nanoparticle payload to cancer cell via molecular linker. Selective delivery and receptor-mediated targeting in oncology. Pharmaceutical development Posters & Papers
Read article Updated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community

This article provides updated recommendations for the bioanalysis of antibody-drug conjugates (ADCs), reflecting more than a decade of advances in the field. Developed by the AAPS ADC Working Group, it addresses key considerations for quantifying total antibody, conjugated ADC, free payload, and drug-to-antibody ratio (DAR), as well as immunogenicity,…

Human antibodies bind to human cell receptors, 3d illustration. Posters & Papers
Read article Neutralizing Antibody Validation Testing and Reporting Harmonization

This article provides harmonized recommendations for the validation and reporting of neutralizing antibody (NAb) assays, addressing challenges associated with both cell-based and non-cell-based formats. Developed by experts from industry and the FDA through the American Association of Pharmaceutical Scientists’ Therapeutic Product Immunogenicity Community, the recommendations cover key assay performance…

Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously. Posters & Papers
Read article Bioanalytical Challenges and Unique Considerations to Support Pharmacokinetic Characterization of Bispecific Biotherapeutics

Bispecific protein therapeutics present unique challenges for pharmacokinetic (PK) characterization because multiple functional domains must be evaluated, along with potential biotransformation and interference from anti-therapeutic antibodies. This review presents case studies and a regulatory perspective on developing PK assay strategies for bispecific molecules, emphasizing the need to consider each…

Blogs
Read article Why Volumetric Absorptive Microsampling (VAMS) Is Transforming Whole Blood Bioanalysis

As drug development programs continue to expand into more complex therapeutic modalities and patient-centric clinical trial designs, bioanalytical laboratories are under increasing pressure to generate high-quality data from smaller, less invasive samples. Volumetric absorptive microsampling (VAMS) has emerged as a promising solution, offering a practical alternative to traditional blood…

KC-Building_KCASBio Videos
Watch Video Kansas City Lab Tour

Full laboratory tour of the KCAS Bio location in Kansas City, KS USA. Interested in speaking with one of our experts? Fill out the form below to connect with a KCAS Bio scientist.

LYON_Building_KCASBio Videos
Watch Video Lyon, France Lab Tour

Full laboratory tour of the KCAS Bio location in Kansas City, KS USA. Interested in speaking with one of our experts? Fill out the form below to connect with a KCAS Bio scientist.

Functional assays in drug development_KCASBio Blogs
Read article Functional Assays in Drug Development: A Complete Guide to Evaluating Biological Activity

What are functional assays? Understanding the interactions between drugs and biological systems is critical for the success of a new drug. One key tool in this process is functional assays. Functional assays in drug development are customized assays that evaluate the impact of drugs on the functionality of cells.

Continuity without Compromise_KCASBio Blogs
Read article Continuity Without Compromise: How KCAS Bio Delivers End‑to‑End Bioanalytical Support Across Modalities

In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in…

Biomarker Webinar webinars
Watch Now Biomarkers Roundtable: Practical Insights for LBA and Molecular Assays

Biomarkers can move a program forward fast. Or slow it down with rework. Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align context of use,…